Pharmaceutical Technology on MSN
Solve Therapeutics raises $120m as MSD joins list of backers
In a year where ADC deals have showed no signs of slowing, Solve has become the latest biotech to unlock an extra slice of ...
Merck Sharp & Dohme (MSD) has agreed to acquire Cidara Therapeutics in a transaction valued at approximately $9.2 billion, ...
Clinical Trials Arena on MSN
MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial
MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).
MSD's cancer immunotherapy Keytruda will soon be available as a subcutaneous injection that does away with the need to visit an infusion clinic. Keytruda Qlex (pembrolizumab and berahyaluronidase alfa ...
Merck & Co (MSD) has announced that it is discontinuing two Phase III Keytruda (pembrolizumab) clinical trials. The KEYNOTE-867 (NCT03924869) trial was evaluating Keytruda plus stereotactic body ...
STOCKHOLM – Elekta (EKTA-B.ST) today announced a partnership with MSD (Merck & Co., Inc., Rahway, N.J., USA) to develop digital patient monitoring for people with advanced renal cell carcinoma (RCC), ...
For five months starting in late 2013, Yvette Downs began her work week at Cincinnati's Metropolitan Sewer District by boarding a plane in Washington, D.C. Downs, who was MSD’s senior financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback